45 Participants Needed

NAC Eye Drops for Fuchs' Dystrophy

KM
SE
UJ
Overseen ByUla Jurkunas, MD
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Massachusetts Eye and Ear Infirmary
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

You may need to stop using certain eye medications, except for lubricants, hyperosmotic agents, or ocular hypotensive agents. If you're using N-Acetylcysteine in any form, you'll need to stop at least 30 days before joining the trial.

What data supports the effectiveness of the drug N-acetyl cysteine (NAC) eye drops for Fuchs' Dystrophy?

Research shows that N-acetyl cysteine (NAC) can help protect corneal cells from stress and improve their survival in a mouse model of Fuchs' Dystrophy, suggesting it might be beneficial for this condition.12345

Is N-acetylcysteine (NAC) generally safe for human use?

N-acetylcysteine (NAC) has been used safely for several decades as a treatment for conditions like acetaminophen poisoning and respiratory diseases, but it can cause some adverse reactions in humans.12367

How is the drug N-acetyl cysteine (NAC) unique for treating Fuchs' Dystrophy?

N-acetyl cysteine (NAC) eye drops are unique for treating Fuchs' Dystrophy because they help protect corneal cells from oxidative stress (damage caused by harmful molecules) and endoplasmic reticulum stress (cellular stress related to protein folding), which are key factors in this condition. This approach is different from other treatments that may not specifically target these stress pathways.12489

What is the purpose of this trial?

This trial tests if NAC eye drops can protect eye cells by reducing harmful oxidative stress in patients with advanced FECD and cataracts. The study involves patients who are already scheduled for eye surgeries. NAC is expected to help by protecting the corneal cells from damage. NAC has been used topically in the treatment of various eye conditions due to its antioxidant, anti-inflammatory, and mucolytic properties.

Research Team

UJ

Ula Jurkunas, MD

Principal Investigator

Mass Eye and Ear

Eligibility Criteria

This trial is for adults over 21 with advanced Fuchs' Endothelial Corneal Dystrophy (FECD) and cataracts needing surgery. Participants must be able to follow the medication plan and not be pregnant, breastfeeding, or unwilling to use birth control. They shouldn't have had previous eye surgeries in the study eye or used certain medications recently.

Inclusion Criteria

I need surgery for a cornea transplant and cataract removal at the same time.
I am 21 years old or older.
Written informed consent obtained from subject and ability for subject to comply with the requirements of the study
See 3 more

Exclusion Criteria

I have a history of serious eye conditions affecting the cornea.
I use eye medication, but only for dryness, swelling, or pressure.
Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study
See 5 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
1 visit (in-person)

Treatment

Participants self-administer NAC or placebo eye drops four times a day for 28 days prior to planned surgery

4 weeks
Weekly check-ins (virtual or in-person)

Surgery

Participants undergo DMEK and cataract surgery, with collection of aqueous fluid and corneal tissue for analysis

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after surgery, including assessment of adverse events and corneal measurements

2-3 weeks
2-3 visits (in-person)

Treatment Details

Interventions

  • N-acetyl cysteine (NAC) 10% solution
  • N-acetyl cysteine (NAC) 20% solution
  • Visine Dry Eye Relief eye drops
Trial Overview The study tests if N-acetyl cysteine (NAC) eye drops can reduce oxidative stress and protect cells in patients with FECD. It compares Visine Dry Eye Relief drops, NAC 10% solution, and NAC 20% solution applied topically before corneal surgery.
Participant Groups
3Treatment groups
Active Control
Placebo Group
Group I: NAC 20% groupActive Control1 Intervention
Subjects in this group will be treated with eye drops containing a 20% solution of N-acetyl cysteine. Topical NAC is a well-tolerated medication that has many applications in ophthalmology including dry eye disease and meibomian gland dysfunction.
Group II: NAC 10% groupActive Control1 Intervention
Subjects in this group will be treated with eye drops containing a 10% solution of N-acetyl cysteine. Topical NAC is a well-tolerated medication that has many applications in ophthalmology including dry eye disease and meibomian gland dysfunction.
Group III: Placebo groupPlacebo Group1 Intervention
Subjects in this group will be treated with a placebo (Visine Tears Dry Eye Relief artificial tears ophthalmic solution.)

N-acetyl cysteine (NAC) 10% solution is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Acetylcysteine for:
  • Mucolytic agent
  • Acetaminophen antidote
  • Dry eye disease
🇪🇺
Approved in European Union as N-acetyl cysteine for:
  • Mucolytic agent
  • Paracetamol overdose
  • Dry eye disease
🇨🇦
Approved in Canada as Acetylcysteine for:
  • Mucolytic agent
  • Acetaminophen antidote

Find a Clinic Near You

Who Is Running the Clinical Trial?

Massachusetts Eye and Ear Infirmary

Lead Sponsor

Trials
115
Recruited
15,000+

Findings from Research

N-acetylcysteine (NAC) significantly improves the survival of corneal endothelial cells under oxidative and endoplasmic reticulum stress, as shown by increased cell viability in cultured cells pre-treated with NAC.
In a mouse model of early-onset Fuchs endothelial corneal dystrophy, systemic NAC treatment led to higher corneal endothelial cell density and lower cell stress markers, suggesting it could be a promising treatment for this condition.
N-Acetylcysteine increases corneal endothelial cell survival in a mouse model of Fuchs endothelial corneal dystrophy.Kim, EC., Meng, H., Jun, AS.[2022]
In a study involving 79 eyes of 40 patients with chronic posterior blepharitis, N-acetylcysteine (NAC) significantly improved the fluorescein break-up time (FBUT) and mucous fern pattern, indicating enhanced tear stability and eye surface health.
The mechanism of action for NAC in this context is believed to involve the blocking of lipid peroxidation, which may help alleviate symptoms of chronic blepharitis.
N-acetylcysteine in chronic blepharitis.Yalçin, E., Altin, F., Cinhüseyinoglue, F., et al.[2019]
N-acetylcysteine (NAC) is a powerful antioxidant that helps protect cells from oxidative stress by boosting levels of glutathione (GSH), which is crucial for cellular defense against damage.
NAC has a variety of clinical applications, including treating respiratory diseases, serving as an antidote for acetaminophen poisoning, and showing potential benefits in neuropsychiatric disorders by modulating glutamate levels.
The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress.Raghu, G., Berk, M., Campochiaro, PA., et al.[2022]

References

N-Acetylcysteine increases corneal endothelial cell survival in a mouse model of Fuchs endothelial corneal dystrophy. [2022]
N-acetylcysteine in chronic blepharitis. [2019]
3.United Arab Emiratespubmed.ncbi.nlm.nih.gov
The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. [2022]
Release of N-acetylcysteine and N-acetylcysteine amide from contact lenses. [2013]
Evaluation of the Effect of N-Acetylcysteine on Protein Deposition on Contact Lenses in Patients with the Boston Keratoprosthesis Type I. [2015]
N-acetylcysteine in handgrip exercise: plasma thiols and adverse reactions. [2021]
Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. [2018]
A Controlled, Randomized Double-Blind Study to Evaluate the Safety and Efficacy of Chitosan-N-Acetylcysteine for the Treatment of Dry Eye Syndrome. [2018]
Effects of Topical Mucolytic Agents on the Tears and Ocular Surface: A Plausible Animal Model of Mucin-Deficient Dry Eye. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security